References

nogr

Экспериментальная и клиническая гастроэнтерология

Experimental and Clinical Gastroenterology

1682-8658

«Global Media Technologies»

nogr-284

Research Article

КЛИНИЧЕСКАЯ ФАРМАКОЛОГИЯ

CLINICAL PHARMACOLOGY

ГЕПАТОПРОТЕКТОР РОПРЕН ДЛЯ ЛЕЧЕНИЯ БОЛЬНЫХ С НЕАЛКОГОЛЬНЫМ СТЕАТОГЕПАТИТОМ: ОБСЕРВАЦИОННОЕ ПРОГРЕССИВНОЕ ИССЛЕДОВАНИЕ

THE HEPATOPROTECTOR ROPREN FOR THE TREATMENT OF PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS: A PROSPECTIVE OBSERVATIONAL STUDY

Голованова

Е. В.

Golovanova

E. V.

noemail@neicon.ru

Шапошникова

Н. А.

Shaposhnikova

N. A.

noemail@neicon.ru

Мелькина

Е. С.

Melkina

E. S.

noemail@neicon.ru

Султанов

В. С.

Soultanov

V. S.

vagif.soultanov@solagran.com

Московский государственный медико-стоматологический университет им. А.И. ЕвдокимоваРоссияState Budget Educational Institution of Higher Professional Education (SBEI HPE) A. I. Evdokimov Moscow State University of Medicine and Dentistry Ministry of Healthcare of RussiaRussian Federation

Государственное бюджетное учреждение города Москвы Московский клинический научный центр Департамента Здравоохранения города МосквыРоссияMoscow Clinical Scientific Center, Department of Public Health of MoscowRussian Federation

Федеральное государственное бюджетное образовательное учреждение высшего образования «Санкт-Петербургский государственный лесотехнический университет имени С.М. Кирова»; Пренолика Лимитед, Биотехнологическая компанияРоссияSaint Petersberg State Forest Technical Academy; Prenolica Limited, Biotechology CompanyRussian Federation

2016

20092016

097176

2016

Голованова Е.В., Шапошникова Н.А., Мелькина Е.С., Султанов В.С.

Golovanova E.V., Shaposhnikova N.A., Melkina E.S., Soultanov V.S.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.nogr.org/jour/article/view/284

Objectives. New and effective drugs to improve liver function and fibrosis are urgently needed for patients with nonalcoholic steatohepatitis (NASH). This study examines the effectiveness of treatment of patients with NASH with the registered hepatoprotector, Ropren®. Methods. This observational study used Ropren® in a post-registration setting to treat 20 females (38-56 years) with chronic NASH unresponsive to standard treatment. Ropren® is a biopolymer made up of polyprenols (analogue of dolichol) isolated from the green verdure of spruce (Picea abies (L) Karst). Ropren® was given orally, three times a day (54 mg/day). Measurements before and after treatment included symptoms and blood biochemistry (triglycerides, high-density lipoproteins, low-density lipoproteins, alanine transaminase, aspartate transaminase, alkaline phosphatase and gamma-glutamyl-transpeptidase). Liver fibrosis was measured with indirect ultrasound elastometry. Results. After 12 weeks of Ropren® treatment, improvements were found for blood lipids and clinical and biochemical signs, including reductions in total cholesterol and triglycerides (p < 0.05). Ropren® also significantly decreased the liver fibrosis index (p < 0.05). No side effects were observed. Conclusions. Ropren® treatment increased the elasticity of the liver and might be useful to reduce the risk of cirrhosis. Although the sample size in this study was small, the results demonstrated that a randomised-controlled trial of Ropren® for NASH is warranted.

non-alcoholic steatohepatitisNASHlipidpolyprenolsdolicholhepatoprotectorsBioeffectiveRopren®

References1

Vajro P., Lenta S., Pignata C., Salerno M., D’aniello R., De Micco I., Paolella G., and Parenti. Therapeutic options in pediatric non alcoholic fatty liver disease: current status and future directions, Italian Journal of Pediatrics, vol. 38, p.55, 2012.

Pinzani P. Pathophysiology of non-alcoholic steatohepatitis and basis for treatment, Digestive Diseases, vol. 29, no. 2, pp. 243-248, 2011.

Friis-Liby I., Aldenborg F., Jerlstadt P., Rundström K., Björnsson E. High prevalence of metabolic complications in patients with non-alcoholic fatty liver disease, Scandinavian Journal of Gastroenterology, vol. 39, no. 9, pp. 864-869, 2004.

Adams L. A., Waters O. R., Knuiman M.W., Elliot R. R., Olynyk J. K. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study, American Journal of Gastroenterology, vol. 104, no. 4, pp. 861-867, 2009.

Takamura T., Misu H., Ota T., Kaneko S. Fatty liver as a consequence and cause of insulin resistance: lessons from type 2 diabetic live, Endocrine Journal, vol. 59, no. 9, pp. 745-763, 2012.

Treeprasertsuk S., Björnsson E., Enders F. NAFLD fibrosis score: A prognostic predictor for mortality and liver complications among NAFLD patients, World Journal of Gastroenterology, vol. 19, no. 8, pp. 1219-1229, 2013.

Kim D., Kim W. R., Kim H. J, Therneau T. M. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States, Hepatology, vol. 57, no. 4, pp. 1357-1365, 2013.

Zvenigorodskaya L. A., Egorova E. G. Hepatic Lesions at insulin resistance, Eksperimental’naija i Klinicheskaija gastroenterologiija, vol. 1, pp. 14-19, 2007.

Lazebnik L. B., Zvenigorodskaya L. A., Yegorova E. G. Metabolic syndrome in patients with gastrointestinal diseases, Terapevticheskii Arkhiv vol. 79, no. 10, pp. 9-13, 2007.

Shuppan D., Pinzani M. Anti-fibrotic therapy: Lost in translation?, J Hepatology, vol. 56 (Suppl 1), pp. S66-S74, 2012.

Саггоll K.K. Studies on the distribution and metabolism of dolichol and related compounds, Chemica Scripta, vol. 27, no. 1, pp. 73-77, 1987.

Chojnacki T., Dallner G. Тhе biological гоlе of dolichol, Biochemical Journal, vol. 251, no. 1, pp. 1-9, 1988.

Crick D, Carroll K. Absorption and distribution of [1-14С] dolichol into rats, Biochemistry and Cell Biology, vol. 65, no. 4, pp. 317-320, 1987.

Кееnаn R., Fisher J., Kruzcek J. Тhe tissue and subcellular distribution of [1-3Н] dolichol in the rаt, Аrсhives of Biochemistry and Biophysics, vol. 179, no. 2, pp. 634-642, 1977.

Jakobsson A., Swiezewska E., Chojnacki T., Dallner G. Uptake and modification of dietary polyprenols and dolichols in гаt liver, FEBS Letters, vol. 255, no. 1, pp. 32-36, 1989.

Keller R. Dolichol metabolism in гаt, Trends in Biochemical Sciences, vol. 12, pp. 443-445, 1987.

Кlimov A. N., Constantinov V. O., Lipovetsky B. M., Kuznetsov A. S., Lozovsky V. T., Trufanov V. F., Plavinsky S. L., Gundermann K-J., Schumacher R. “Essential” phospholipids versus nicotinic acid in the treatment of patients with type IIb hyperlipoproteinemia and ischemic heart disease, Cardiovascular Drugs and Тhеrapy, vol. 9, no. 6, pp. 779-784, 1995.

Lieber C. S., Robin S. I., Li J., DeCarli L. M., Mak K. M., Fasulo J. M., Leo M. A. Phosphatidylcholine protects against fibrosis and cirrhosis baboon, Gastroenterology, vol. 106, no. 1, pp. 152-159, 1994.

Pullarkat R. K., Ragutu S., Pachchagiri S. Dolichols in metastatic саncer, Transactions of the Аmerican Society for Neurochemistry, vol. 15,p. 171, 1984.

Rupar C., Carroll K. Occurrence of dolichol in human tissues, Lipids, vol. 13, no. 4, pp. 291-293, 1978.

Steinke D. T., Weston T. I., Morris A. D., MacDonald T.M., Dillon J. F. Тhe epidemiology of liver disease in Tayside database: а population-based record linkage study, Journal of Biomedical Informatics, vol. 35, no. 3, pp. 186-193, 2002.

Cantagrel V., Lefeber D. J., Ng B. G., Guan Z., Silhavy J.L., Bielas S. L., Lehle L., Hombauer H., Adamowicz M., Swiezewska E., De Brouwer A. P., Blümel P., Sykut-Cegielska J., Houliston S., Swistun D., Ali B.R., Dobyns W.B., Babovic-Vuksanovic D., van Bokhoven H., Wevers R. A., Raetz C. R. H., Freeze H. H., MoravaE., Al-Gazali L. SRD5A3 is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorder, Cell vol. 142, no. 2, pp. 203-217, 2010.

Sviderskii V. L., Soultanov V. S., Roschin V.I., Khovanskikh A.E., at all. Analysis of the effect of the polyprenol preparation ropren and the choline alphoscerate preparation gliatilin on the membrane-bound and soluble forms of cholinesterases and monoamine oxidase of rat brain and serum in the tetrachloromethane model system of hepatic encephalopathy, Doklady Biochemisrty and Biophysics, vol. 412, no. 1 pp. 33-36, 2007.

Zarubaev V. V., Soultanov V. S., Soukhinin V. P. Studying the dynamics of the interferon-related activity of "Ropren" and the modified drugs in tests on white mice, Fourth International Conference, Pasteur's ideas in control of infections, vol. 12, 2008.

Fedotova J., Soultanov V., Nikitina T., Roschin V., Ordyan N., Hritcu L. Ropren® is a polyprenol preparation from coniferous plants that ameliorates cognitive deficiency in a rat model of beta-amyloid peptide-(25-35)-induced amnesia, Phytomedicine, vol. 19, pp. 451-456, 2012.

Fedotova J., Soultanov V., Nikitina T., Roschin V., Ordyan N., Hritcu L. Cognitive-enhancing activities of the polyprenol preparation Ropren® in gonadectomized β-amyloid (25-35) rat model of Alzheimer's disease, Physiology & Behavior, vol. 157, pp. 55-62, 2016.

Khodanovich M., Glazacheva V., Pan E., Akulov A., Krutenkova E., Trusov V., Yarnykh V. MRI study of the cuprizone-induced mouse model of multiple sclerosis: demyelination is not found after co-treatment with polyprenols (long-chain isoprenoid alcohols), Journal of Physics: Conference Series 677 (2016) 012007, 2016.

Soultanov V., Fedotova J., Nikitina T., Roschin V., Ordyan N., Hritcu L. Antidepressant-like effect of Ropren® in β-amyloid-(25-35) rat model of Alzheimer’s disease with altered levels of androgens, Molecular Neurobiology, EPUB ahead of print, March 19. DOI 10.1007/s12035-016-9848-8, 2016.

Soultanov V. S., Shabanov P. D., Roschin V. I. Ropren - The first polyprenol pharmaceutical drug in the world for the treatment of diseases of the liver and brain, Pharmacology Bulletin, no 2-3, pp. 35-47, 2012.

Lapteva E. N., Roschin V. I., Soultanov V. S. Specific activity of polyprenol- based Ropren in toxic liver damage in a trial [in Russian], Clinical Nutrition, vol. 1, pp. 25-29, 2006.

Soultanov V. S., Roschin V. I., Lapteva E. N. Utilisation of a new therapeutic substance, Ropren, in patients with diseases of hepatobiliary system, as well as with alcohol, narcotic and drug intoxication, Fourth International Conference, Pasteur's ideas in control of infections, pp. 166-168, 2008.

Soultanov V.S., Agishev V.G., Monakhova I.A., Mokhovikova I.A., Kulikov A.P., Roschin V.I., Nikitina T.V. Ropren® improves liver and pancreatic function in patients with chronic alcoholism, Gastroenterology Saint Petersburg, no 4, pp. 12-17, 2010.

Roschin V.I., Raldugin V.A., Poverinova O.Y., Nagibina N.Yu., Demenkova L.I., Kukina T.P. Season dynamics of distribution of bonded polyprenol and dolichol isoprenologs in leaves and shoots of Alnus glutinosa, Bulletin of the Russian Academy of Sciences, no. 5, pp. 1016-1019, 1999.

Roschin V. I., Sultanov V. S. Method of processing plant raw materials, PCT RU 2004/00162, 2004.

State Pharmacopoeia of the Russian Federation, XII, (Moscow 2007) [in Russian]

Quarty G., Feudjo-Tepie M., Wang J., Kim J. Opportunities for minimisation of confounding in observational research, Pharmaceutical Statististics vol. 10, no. 6, pp. 539-547, 2011.

The authors declare that there are no conflicts of interest present.